Review
Mitoxantrone: potential for use in intensive therapy
Affiliations
- PMID: 2406923
Item in Clipboard
Review
Mitoxantrone: potential for use in intensive therapy
Semin Oncol.
1990 Feb.
Abstract
Mitoxantrone is a synthetic anthraquinone that is active in the therapy of a number of malignancies. At standard doses, toxicity has been primarily myelosuppressive with little extramedullary toxicity. These features in conjunction with evidence that mitoxantrone displays a dose-response effect in vitro make it an attractive candidate for intensive therapy regimens. The data to support the development of mitoxantrone for intensive programs and the clinical evidence that it can be substantially dose escalated are reviewed.
Similar articles
-
Dose escalation of mitoxantrone given with thiotepa and autologous bone marrow transplantation for metastatic breast cancer.Bone Marrow Transplant. 1993 Nov;12(5):525-30. Bone Marrow Transplant. 1993. PMID: 8298564 Clinical Trial.
-
Toxicoses associated with administration of mitoxantrone to dogs with malignant tumors.J Am Vet Med Assoc. 1991 May 1;198(9):1613-7. J Am Vet Med Assoc. 1991. PMID: 2061176
-
High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors.Cancer Res. 1989 Aug 15;49(16):4654-8. Cancer Res. 1989. PMID: 2545349
-
Mitoxantrone: a novel anthracycline derivative.Clin Pharm. 1988 Aug;7(8):574-81. Clin Pharm. 1988. PMID: 3048848 Review.
-
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12. Cancer Chemother Pharmacol. 2002. PMID: 12042984 Review.
Cited by
-
Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.Drugs. 1991 Mar;41(3):400-49. doi: 10.2165/00003495-199141030-00007. Drugs. 1991. PMID: 1711446 Review.
-
Comparison of mitoxantrone and tetracycline as pleural sclerosing agents in rabbits.Lung. 1996;174(6):373-81. doi: 10.1007/BF00164634. Lung. 1996. PMID: 8887932
-
Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies.Invest New Drugs. 1993 Nov;11(4):291-300. doi: 10.1007/BF00874427. Invest New Drugs. 1993. PMID: 8157471 Clinical Trial.